Two major partnerships expand access to Visby's at-home sexual health test for women
Quest and Labcorp now offer more choices
Visby Medical has announced new distribution partnerships with Quest Diagnostics and Labcorp, expanding national consumer access to its women’s sexual health test - the first FDA- authorized at-home PCR test for sexually transmitted infections.
The move positions Visby in one of the most impactful shifts in women’s health right now: decentralized, at-home diagnostics that can close long-standing gaps in access, speed and privacy.
STI testing remains slow, fragmented, and delayed
STIs remain both common and chronically underdiagnosed. Many infections are asymptomatic, particularly in women, yet can lead to pelvic inflammatory disease, infertility, and other long-term complications if untreated. Nearly 100,000 women in the US lose their fertility each year due to complications from untreated STIs, according to data cited by Visby.
Despite this, testing often requires in-person clinic visits or at-home kits that still rely on mailing samples to centralized labs—introducing delays that can stretch from days to over a week. In infectious disease management, those delays matter, not only for individual outcomes but for onward transmission.
The Visby difference: PCR results in 30 minutes, at home
Visby’s Women’s Sexual Health Test is designed to remove that waiting period entirely. Using PCR technology—the gold standard for molecular diagnostics—the palm-sized, single-use device delivers results for chlamydia, gonorrhea, and trichomoniasis in approximately 30 minutes. There is no need to mail samples.
Users collect a vaginal swab, insert it into the device, and receive results through Visby’s secure mobile app. That immediacy underpins what the company describes as a “test-to-treat” ecosystem, enabling same-day virtual care and prescriptions where appropriate.
“Infectious disease management relies heavily on the speed of diagnosis, and for too long, women’s health has been hindered by delays,” said Gary Schoolnik, MD, chief medical officer of Visby Medical. “When a patient has to wait days for a result, we risk the infection spreading or developing into Pelvic Inflammatory Disease.”
Broader distribution through familiar consumer health channels
Under the new agreements, consumers can now purchase the Visby test via questhealth.com, the consumer-initiated testing platform operated by Quest Diagnostics. The test has been available on the platform since November 2025 and includes access to same-day virtual care and treatment through a third-party provider if results are positive.
Separately, the test is now available through Labcorp OnDemand, Labcorp’s digital testing platform. Labcorp has also confirmed plans to extend access via Ovia Health, integrating the Visby test into Ovia’s offerings for employer and health plan partners in early 2026.
For Quest and Labcorp, the partnerships reflect a growing willingness among incumbent diagnostics players to support consumer-facing, decentralized testing models—particularly in women’s health, where stigma, scheduling barriers, and privacy concerns often suppress uptake.
“As a physician, I see firsthand how a timely and accurate diagnosis is critical to preventing complications from STIs,” said Dr. Leslie Saltzman, medical discipline director for consumer health at Labcorp.
“Collaborating with Visby allows us to offer a fully at-home option that combines accuracy, privacy, and convenience.”
Visby’s expansion arrives amid a wider industry shift toward bringing diagnostics closer to patients—whether in the home, workplace, or community setting. COVID-19 normalized rapid, self-administered testing, and women’s health innovators are increasingly applying similar models to reproductive health, fertility, and sexual health. As women’s health continues to embrace this decentralization, the next phase will be about integration with care pathways, reimbursement models, and public health strategies.